As of 2024-12-14, the Intrinsic Value of 4D Molecular Therapeutics Inc (FDMT) is
2.80 USD. This FDMT valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 6.50 USD, the upside of 4D Molecular Therapeutics Inc is
-57.00%.
The range of the Intrinsic Value is 0.12 - 3.32 USD
FDMT Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
0.12 - 3.32 |
2.80 |
-57.0% |
| DCF (Growth 10y) |
2.27 - (5.07) |
1.08 |
-83.4% |
| DCF (EBITDA 5y) |
3.45 - 3.31 |
3.38 |
-47.9% |
| DCF (EBITDA 10y) |
2.59 - 2.11 |
2.36 |
-63.6% |
| Fair Value |
-22.93 - -22.93 |
-22.93 |
-452.81% |
| P/E |
(126.40) - (139.80) |
(123.38) |
-1998.1% |
| EV/EBITDA |
(67.63) - 5.36 |
(33.99) |
-622.9% |
| EPV |
(15.48) - (22.87) |
(19.18) |
-395.0% |
| DDM - Stable |
(32.24) - (122.85) |
(77.54) |
-1292.9% |
| DDM - Multi |
(0.38) - (1.18) |
(0.59) |
-109.0% |
FDMT Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
300.50 |
| Beta |
1.58 |
| Outstanding shares (mil) |
46.23 |
| Enterprise Value (mil) |
112.96 |
| Market risk premium |
4.60% |
| Cost of Equity |
10.66% |
| Cost of Debt |
5.00% |
| WACC |
7.16% |